Disclosures: Marc Sherman: Nothing to Disclose, Daniel Schafer: Nothing to Disclose, Molly Thomas: Johnson and Johnon: Stock privately held company, Alan Mullen: Nothing to Disclose, Georg Lauer: GSK: Grant/Research Support, GSK: Consultant, Alexandra-Chloe Villani: Nothing to Disclose, Wolfram Goessling: Nothing to Disclose 2460 AN ELEVATED BASELINE LEVEL OF ALKALINE PHOSPHATASE, ALANINE AMINOTRANSFERASE, AND ASPARTATE AMINOTRANSFERASE PREDICT A LACK OF BIOCHEMICAL RESPONSE TO UDCA THERAPY AMONG HISPANIC PATIENTS LIVING WITH PRIMARY BILIARY CHOLANGITIS: A RETROSPECTIVE, PROPENSITY SCORED-MATCHED, COHORT STUDY Luis Alejandro Rosales Renteria 1 Maria Sarai Gonzalez Huezo 2 Gonzalo Pea-Arellano 2 Jorge Alejandro Lpez Cossio 2 Marcela Morales Ibarra 2 Jose David Prieto Nava 2 , 1 Centro Mdico ISSEMyM Toluca, 2 Centro Medico ISSEMyM Toluca Background: Primary biliary cholangitis ( PBC ) is a chronic, progressive, autoimmune liver disease characterized by the destruction of the small bile ducts within the liver

Understanding how 5-amino-1mq fits this landscape helps researchers develop coherent protocols that address their specific goals
Regular follow-ups with our medical team allow us to assess your progress and adjust the treatment plan as needed to optimize your results
Benefits for Skin Appearance One of the biggest reasons people choose an L-Glutathione and Vitamin C Supplement is to support skin appearance
Monopoli, M